Precision BioSciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is DTIL moving today?
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DTIL.
DTIL insider activity
Precision BioSciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$412K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-18 | Amoroso Michael | Insider | sell | $3.84 | 20,559 | 243,392 | $79K | SEC Form 4 |
| 2026-02-19 | 2026-02-18 | Kelly John Alexander | Insider | sell | $3.84 | 8,149 | 125,883 | $31K | SEC Form 4 |
| 2026-02-19 | 2026-02-18 | Scimeca Dario | Insider | sell | $3.84 | 4,925 | 56,457 | $19K | SEC Form 4 |
| 2026-02-19 | 2026-02-18 | SMITH J. JEFFERSON | Insider | sell | $3.84 | 4,925 | 121,926 | $19K | SEC Form 4 |
| 2026-01-22 | 2026-01-22 | Amoroso Michael | Insider | sell | $4.17 | 34,799 | 196,154 | $145K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 11 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moDTIL contract awards, year to date.
Public federal awards linked to this ticker.
DTIL lobbying filings, year to date.
Registered lobbying filings matched to Precision BioSciences, Inc. Common Stock.